Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03346824

Acronym

LEVO-ECMO

Enrollment

Registered

2017-11-17

Start date

2017-11-15

Completion date

2019-01-31

Last updated

2018-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic Shock

Keywords

Levosimendan, Veno-arterial ECMO, Weaning

Brief summary

Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age over 18 * Patient requiring the need for short-term assistance * Patient who has agreed to use his medical data for research purposes

Exclusion criteria

* Refusal to participate in the study * Non-weaning attempts due to a death under assistance or a relay by a long-term assistance or heart transplant * Non-cardiac indications of assistance (indication of pulmonary replacement) * Subject under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame
Comparison of the incidence of weaning failure between patients with levosimendan and others	Data were recorded from admission until 48 hours after weaning from ECMO

Countries

France

Contacts

Primary ContactGharib AJOB, MD

gharib.ajob@chru-strasbourg.fr33 3 69 55 15 70

Backup ContactGuillaume HAFFNER, MD

guillaume.haffner@chru-strasbourg.fr33 3 69 55 15 70

Outcome results